Contributions
Abstract: EP1757
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Introduction: In the Netherlands 11 Disease Modifying Drugs (DMDs) are registered for Relapsing Remitting Multiple Sclerosis (RRMS) and there are more to come. Some DMDs need risk-based monitoring (RM), however uniformity is lacking. We aim to design one channel for all regimens, including alerts and an active role for the patient.
In the Netherlands 1125 multiple sclerosis (MS) patients are monitored by 28 hospitals monitor via myhealthmonitor.eu/msmonitor (MHM), an online, modular, platform where patients receive, enrich and share their data.
In 2013 the Natalizumab screening APP was added to MHM. The The Natalizumab screening APP consists of 16 questions every 28 days, and must be submitted 2 days prior to the infusion of Natalizumab, sends email reminders. The patient submits the list, the MSnurse can screen the answers and can timely postpone the infusion if needed.
Aims and objective: This study analyses the feasilbility of for RM in a real-life setting.
Methods: Five hospitals use the APP in MHM) in 6o RRMS patients since 2013. MSnurses sign up patients and activate the APP.
Patients were between 22-59 years old, 52 females, 8 males and gave consent.
Results: 53 patients (92%) submitted 860 screeningslists (range 1 - 53 per individual), participated between 1 - 1561 days (mean 565 days). In range with clinical purpose: 648 lists (75,4%) were submitted the same day or the next day.
In this real-life setting patients start and stop. At data-extraction (16th of May 2017), 27 patients were “on track” (last submission before or after 19 April 2017). 33 patients were not “on track”. Reasons for were: never loged on (n=6), Natalizumab was stopped (n=13), personal reasons (n=2), unknown (still using natalizumab) (n=10).
Conclusion: This real-life setting shows that patients are capable of providing information on line for RM “in time” as needed for clinical purposes.
An APP to serve all different schedules for the different DMD's seems a valuable tool to develop in risk-based monitoring in RRMS.
Disclosure:
van Noort, E.M.J. Boardmember of MHM/msmonitor, funded by Teva Pharma Netherlands.
Jongen, P.J.H. Chairman of MHM/msmonitor, funded by Teva Pharma Netherlands
Has received honoraria from Bayer, Merck and TEVA for consultancy activities.
M.J. Kasteleyn: nothing to disclose
J.C.C.M. In 't Veen: nothing to disclose
N.H. Chavannes: nothing to disclose
Abstract: EP1757
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Introduction: In the Netherlands 11 Disease Modifying Drugs (DMDs) are registered for Relapsing Remitting Multiple Sclerosis (RRMS) and there are more to come. Some DMDs need risk-based monitoring (RM), however uniformity is lacking. We aim to design one channel for all regimens, including alerts and an active role for the patient.
In the Netherlands 1125 multiple sclerosis (MS) patients are monitored by 28 hospitals monitor via myhealthmonitor.eu/msmonitor (MHM), an online, modular, platform where patients receive, enrich and share their data.
In 2013 the Natalizumab screening APP was added to MHM. The The Natalizumab screening APP consists of 16 questions every 28 days, and must be submitted 2 days prior to the infusion of Natalizumab, sends email reminders. The patient submits the list, the MSnurse can screen the answers and can timely postpone the infusion if needed.
Aims and objective: This study analyses the feasilbility of for RM in a real-life setting.
Methods: Five hospitals use the APP in MHM) in 6o RRMS patients since 2013. MSnurses sign up patients and activate the APP.
Patients were between 22-59 years old, 52 females, 8 males and gave consent.
Results: 53 patients (92%) submitted 860 screeningslists (range 1 - 53 per individual), participated between 1 - 1561 days (mean 565 days). In range with clinical purpose: 648 lists (75,4%) were submitted the same day or the next day.
In this real-life setting patients start and stop. At data-extraction (16th of May 2017), 27 patients were “on track” (last submission before or after 19 April 2017). 33 patients were not “on track”. Reasons for were: never loged on (n=6), Natalizumab was stopped (n=13), personal reasons (n=2), unknown (still using natalizumab) (n=10).
Conclusion: This real-life setting shows that patients are capable of providing information on line for RM “in time” as needed for clinical purposes.
An APP to serve all different schedules for the different DMD's seems a valuable tool to develop in risk-based monitoring in RRMS.
Disclosure:
van Noort, E.M.J. Boardmember of MHM/msmonitor, funded by Teva Pharma Netherlands.
Jongen, P.J.H. Chairman of MHM/msmonitor, funded by Teva Pharma Netherlands
Has received honoraria from Bayer, Merck and TEVA for consultancy activities.
M.J. Kasteleyn: nothing to disclose
J.C.C.M. In 't Veen: nothing to disclose
N.H. Chavannes: nothing to disclose